Canine hyperadrenocorticism (HAC) is a common and progressive endocrinopathy. Pancreatitis rarely has been reported as a cause of morbidity or mortality in dogs with HAC, but HAC was identified as a risk factor for fatal pancreatitis in 1 study. Clinicopathologic findings consistent with HAC include neutrophilia, lymphopenia, and thrombocytosis; increased serum alanine transferase and alkaline phosphatase (ALP) activities; and increased serum cholesterol, triglyceride, and glucose concentrations. Many of these abnormalities also can occur secondary to pancreatitis. In addition, some biomarkers of pancreatitis are affected by steroid excess. These factors complicate accurate diagnosis of pancreatitis in dogs with HAC.

Canine Pancreatic-Specific Lipase Concentrations in Clinically Healthy Dogs and Dogs with Naturally Occurring Hyperadrenocorticism

D.I. Mawby, J.C. Whittemore, and K.A. Fecteau

Background: Specificity of canine pancreatic lipase immunoreactivity (cPLI) assays in dogs with hyperadrenocorticism (HAC) is unknown.

Hypothesis: Results of cPLI assays differ for clinically healthy dogs and dogs with HAC.

Animals: Seventeen healthy dogs and 20 dogs with HAC diagnosed by ACTH stimulation test results without evidence of clinical pancreatitis.

Methods: Dogs were enrolled between December 2009 and November 2010. Serum cPLI concentrations were determined by quantitative (Spec cPL test, SPEC) and semiquantitative (SNAP cPL test, SNAP) assays. Results were categorized as normal, equivocal, or abnormal (SPEC) or negative or positive (SNAP). Associations between group and cPLI were assessed using Fisher’s exact test or the Mann–Whitney U-test. Spearman rank correlation coefficients (r) were determined for SNAP and SPEC results. Significance was set at P < .05.

Results: Spec cPL test concentrations were significantly (P < .001) higher in dogs with HAC (491.1 µg/L) than in healthy dogs (75.2 µg/L), with more abnormal SPEC results in HAC dogs (P < .001). There were more (P = .002) positive SNAP results in dogs with HAC (55%) than in healthy dogs (6%). SNAP and SPEC results were highly correlated (P = 0.85; P < .001).

Conclusions and Clinical Importance: Dogs with HAC had higher SPEC concentrations and more positive SNAP results than clinically healthy dogs with normal ACTH stimulation test results. Specificity of SPEC and SNAP assays in HAC dogs without clinical pancreatitis were 65 and 45%, respectively. Pending further study, SNAP and SPEC results should be interpreted cautiously in dogs with HAC to avoid false diagnosis of concurrent pancreatitis.

Key words: Cortisol; Cushings; Pancreatitis.

Abbreviations:

ALP alkaline phosphatase
cPLI canine pancreatic lipase immunoreactivity
HAC hyperadrenocorticism
SNAP SNAP cPL test
SPEC Spec cPL test

Currently, serum canine pancreatic lipase immunoreactivity (cPLI) assays are considered the most specific serum biomarkers for the diagnosis of pancreatitis in dogs. Reported specificities for the cPLI assays range from 71 to 100%. Concentrations of cPLI can be estimated using a semiquantitative point-of-care test (SNAP) or measured using a quantitative ELISA test (SPEC). The impact of naturally occurring HAC on cPLI assay results currently is unknown.

The purpose of this study was to compare SPEC and SNAP concentrations in clinically healthy dogs and dogs with HAC diagnosed by ACTH stimulation test results and that did not have clinical pancreatitis. The null hypothesis was that there would be no difference in SPEC concentrations or SNAP results between groups.

Materials and Methods

Study Population

Control Group. Privately owned, healthy dogs (n = 20) were recruited for the study by email to students, staff and faculty at the University of Tennessee College of Veterinary Medicine between October and November 2009. Dogs had to be ≥5 years of age, have received no medications other than routine parasite...
prophylactics within the last 8 weeks, and have no clinical signs of disease or clinically relevant abnormalities on routine physical examination. Exclusion criteria were the presence of abnormalities on plasma biochemistry that persisted on reevaluation or abnormal post-ACTH stimulation test results. The experimental design was approved by the University of Tennessee Institutional Animal Care and Use Committee.

After enrollment in the study, dogs were fasted for 12 hours. Blood was collected at time 0 (t₀), 5 µg/kg ACTH⁸ was administered IV, and a second blood sample was collected 1 hour post-ACTH stimulation (t₁). Plasma (t₀ only) and serum (t₀ and t₁) were separated from collected blood samples within 30 minutes by centrifugation at 8,450 g for 3 minutes. Plasma biochemistry panels and serum cortisol assays⁹ were performed after enrollment of all dogs with HAC. Aliquots of t₀ serum were stored at −80°C, batched, and analyzed for SPEC concentrations and SNAP results with samples from dogs with HAC.

**Dogs with HAC.** Between December 2009 and November 2010, results from samples submitted to the University of Tennessee Clinical Endocrinology Service were reviewed to identify twenty privately owned dogs with HAC for potential enrollment into the study. Initial exclusion criteria were presence of gross hemolysis or inability to obtain blood samples within 30 minutes by centrifugation at 8,450 g for 3 minutes. Plasma biochemistry panels and serum cortisol assays⁹ were performed after enrollment of all dogs with HAC. Aliquots of t₀ serum were stored at −80°C, batched, and analyzed for SPEC concentrations and SNAP results with samples from dogs with HAC.

**Statistical Analysis**

Descriptive statistics were calculated for quantitative variables by study group and analyzed for normality using the Kolmogorov-Smirnov test. Outliers noted on box-and-whisker plots were double-checked to eliminate data entry errors. Analytes with normal distribution for all groups were compared by Student’s t-test (age) or paired Student’s t-test (ACTH stimulation test results), whereas analyses with nonnormal distribution in at least 1 group were compared using the Mann-Whitney U-test (SPEC concentrations). Comparisons of categorical variables (SNAP results and SPEC concentrations by category) between groups were made using Fisher’s exact test. Spearman rank correlation coefficients (ρ) between SPEC concentrations or SPEC diagnostic categories and SNAP results were determined. A value of P < .05 was considered significant for all tests. Statistical analyses were performed and figures created using commercially available statistical software packages.³⁴⁵

**Results**

**Study Population**

Twenty privately owned dogs initially were enrolled in the control group. There were no abnormalities on screening plasma biochemical profiles or ACTH stimulation test results for 16 of the dogs. One dog had increased ALP activity (198 U/L; reference range 15–164 U/L) on initial biochemical screening, but results were within the reference interval (103 U/L) on reevaluation and the dog was retained in the study population. Three dogs had abnormal post-ACTH stimulation serum cortisol concentrations and were excluded from further evaluation. Breeds for the remaining 17 dogs included Labrador Retriever (4), mixed breed (4), Border Collie (2), and 1 each of Chihuahua, Jack Russell Terrier, Rat Terrier, Doberman Pinscher, Mastiff, Staffordshire Terrier, and German Shorthaired Pointer. There were 7 spayed female dogs and 10 male dogs (9 neutered, 1 intact). Mean (±standard deviation [SD]) age was 7.6 (±2) years. No dog in the control group had evidence of clinical disease based on history or physical examination findings.

Twenty dogs with HAC were enrolled. Breeds included mixed breed (5), Dachshund (4), Australian Cattle Dog (3), Labrador Retriever (2), and 1 each of Beagle, Chihuahua, Havanese, Poodle, Shih Tzu, and Yorkshire Terrier. There were 14 spayed female dogs and 6 neutered males. Mean (±SD) age was 10.4 (±2.6) years. Common clinical signs⁸ included polyuria and polydipsia (12), panting (9), polyphagia (5), endocrine alopecia (3), abdominal distention (2), muscle weakness (2), and hypertension (1). Other clinical signs included lethargy (2), urinary tract infection (2), and 1 each for pyoderma, calcium oxalate urolithiasis, and

---

Pancreatic-Specific Lipase Assays

Sera were shipped frozen to the Gastrointestinal Laboratory at Texas A&M University for SPEC analysis¹¹ using a monoclonal antibody and recombinant pancreatic lipase by an individual not associated with the study, so that the investigators performing the SNAP assays would be blinded to results of other assays at the time of assay performance. Results were categorized as negative or positive.

All samples were batched and assayed after study enrollment was completed to limit the impact of interassay variability on results.
weight gain. Dogs had a median of 2 clinical signs (range, 1–4). Diagnostic findings reported included proteinuria (4), adrenomegaly (4), and hypercholesterolemia (1). Eighteen of 20 dogs (90%) had increased serum ALP activities. One dog with polyuria and polydipsia and increased ALP activity had been receiving benazepril chronically for myocardial insufficiency at the time of evaluation.

Age, ACTH stimulation test results, and SPEC concentrations are summarized in Table 1. Healthy dogs were significantly \( (P = .001) \) younger than dogs with HAC. Consistent with inclusion criteria, ACTH stimulation test results were significantly \( (P < .001) \) higher for dogs with HAC than control dogs.

**Pancreatic-Specific Lipase Assays**

Results of the SPEC and SNAP assays are presented in Table 1 and Figures 1–3. Concentrations for SPEC were normally distributed in healthy dogs but not in dogs with HAC. SPEC concentrations were significantly higher in dogs with HAC than in healthy dogs \( (P < .001, \text{Fig } 1) \). The distribution of categorized SPEC results between groups was significantly different \( (P < .001, \text{Fig } 2) \), with significantly more dogs with HAC (7 dogs; 35%) with SPEC concentrations \( \geq 400 \mu g/L \) than healthy dogs (0 dogs; 0%). There also were significantly \( (P = .002, \text{Fig } 3) \) more HAC dogs with positive SNAP results (9 dogs; 55%) than healthy dogs (1 dog; 6%). There was good correlation between SNAP assay results and SPEC concentrations \( (\rho = 0.81, P < .001) \).

**Discussion**

To the authors’ knowledge, this study documents for the first time an association between naturally occurring HAC and increased cPLI assay results in dogs without clinical signs of pancreatitis. The goal of analyzing data for both SPEC and SNAP assays was to allow assessment of both potential association and diagnostic impact. Categorization of SPEC allowed determination of specificity using current clinical diagnostic cut-offs. In this study, SPEC concentrations were significantly higher in dogs with HAC than in healthy dogs. Using the established diagnostic cut-off value of 400 \( \mu g/L \) for pancreatitis, SPEC had a specificity of 65% for dogs with HAC, and a specificity of 40% when a cut-off value of 200 \( \mu g/L \) was applied. There also were significantly more positive

---

**Table 1.** Age and results of ACTH stimulation tests and SPEC concentrations for healthy dogs and dogs with hyperadrenocorticism (HAC).

| Analyte                | Reference Interval | Healthy Dogs \( (n = 17) \) | Dogs with HAC \( (n = 20) \) |
|------------------------|--------------------|-------------------------------|-------------------------------|
| Age                    |                    | Mean Median (Range)           | Mean Median (Range)           |
| Baseline cortisol      | 2.0–58.8 ng/mL     | 7.6 8.0 (5–13)                | 10.4 11.0 (6–14)              |
| Post-ACTH cortisol     | 65.0–174.6 ng/mL   | 119.2 117.5 (72–172)          | 367.4 368.4 (218–501)         |
| SPEC \( \leq 200 \mu g/L \) | 75.2 37.0 (29–287) | 491.1 248.5 (59–4,248)        |

\( ^a \)Dogs with HAC were significantly \( (P = .001) \) younger than healthy dogs.

\( ^b \)Results were significantly higher \( (P < .001) \) for dogs with HAC than for healthy dogs.
SNAP results in dogs with HAC than in clinically healthy dogs, resulting in a specificity for the SNAP of 45% in dogs with naturally occurring HAC. Based on the results of this study, 35 and 55% of dogs with HAC that did not have clinical signs of pancreatitis could have been falsely categorized as having pancreatitis based on the SPEC and SNAP assays, respectively. Therefore, cPLI assays should be interpreted cautiously in dogs diagnosed with, or suspected of having, HAC that are being evaluated for potential concurrent clinical pancreatitis.

Increased canine cPLI concentrations currently are the most specific biomarkers for canine pancreatitis, with sensitivities ranging from 21 to 94% depending on disease severity. Specificity of the SPEC assay for pancreatitis ranges from 66 to 100% depending on the study population and cut-off value used (200 and 400 \( \mu g/L \)).

Increased canine cPLI concentrations can be increased in dogs receiving potassium bromide, phenobarbital, or some other medications. These increases could be because of drug-induced pancreatitis, but alternate possibilities cannot be excluded.

The effects of hypercortisolism on cPLI assays also have been evaluated. Prednisone (2.2 mg/kg/d) was administered PO to 6 young-adult female dogs with X-linked hereditary nephritis for 27 days with no influence on SPEC concentrations. In contrast, both SNAP results and SPEC concentrations were significantly higher in dogs with naturally occurring HAC than in healthy dogs in this study. One explanation for the discordance in results is that this study had higher statistical power than the previous study. Alternatively, the duration of steroid administration in the previous study could have been insufficient to result in altered SPEC concentrations. HAC develops insidiously, and it is likely that dogs with HAC had been experiencing steroid excess for >1 month at the time of diagnosis. The association between HAC and cPLI concentrations in this study could reflect vascular hepatopathy secondary to HAC. Approximately 30% of dogs with vacuolar hepatopathy have increased bile acids concentrations, consistent with hepatic dysfunction. Abnormal cPLI concentrations have been reported in some dogs with hepatopathies. Although hepatic biopsies were not obtained, 90% (18/20) of the dogs in this study had increased ALP activities. Because glomerular filtration rate is increased in dogs with HAC, alterations in renal clearance are unlikely to have affected results of this study.

Because diagnostic evaluation was not standardized, some dogs with HAC could have had subclinical pancreatitis (ie, histologic inflammation of the pancreas without clinical signs of abdominal pain, vomiting, or diarrhea). Whether the chronic steroid excess present in dogs with HAC predisposes them to subclinical pancreatitis remains unresolved. In 1 retrospective evaluation, 8/70 dogs (11.4%) with fatal acute pancreatitis had a previous diagnosis of HAC, consistent with a 4.3-fold increase in the risk of pancreatitis. However, half of the dogs with HAC in that study had been receiving medical management for HAC before developing pancreatitis. Because of the retrospective nature of the study, the presence of confounding factors, including dyslipidemias, is unknown. Review of several long-term evaluations of dogs with naturally occurring HAC did not identify a similar pattern of overrepresentation. Experimental studies in dogs also support a lack of association between glucocorticoid excess and pancreatitis. Experimentally induced chronic steroid excess resulted in increased production and release of pancreatic enzymes into the duodenum without development of clinical pancreatitis. Investigators were unsuccessful in inducing pancreatitis in an ex vivo perfused canine pancreas model after infusion of 200 and 400 mg methylprednisolone and methylprednisolone administration has been shown to have protective effects against hypovolemia-induced pancreatitis.

**Fig 3.** The distribution of SNAP results differed significantly (\( P = .002 \)) between healthy dogs and dogs with hyperadrenocorticism.
At present, prednisone has been administered to dogs at 1.2 mg/kg/d PO or 4 mg/kg/d PO or IV for 14 days without development of clinical or histologic pancreatitis.\(^27\) Finally, neither histologic nor clinical pancreatitis occurred in dogs receiving dexamethasone at 0.6 mg/kg/d SC for 21 days or receiving a 7-day, high-dose tapering protocol.\(^29\) Abdominal ultrasound examination of all dogs by a board-certified radiologist would have been helpful to detect morphologic changes in the pancreas, although benign pancreatic hypertrophy can have a similar appearance to pancreatitis in some cases. Because histologic lesions can be highly localized,\(^30\) collection of pancreatic biopsies would not have eliminated the possibility of occult inflammation. Conversely, the clinical relevance of mild histologic inflammation remains unclear.\(^7,31\)

Alternately, the association between HAC and abnormal cPLI results may relate to underlying dyslipidemia. Both hypercholesterolemia and hypertriglyceridemia occur in dogs with HAC.\(^1\) A syndrome known as benign pancreatic hyperenzymemia has been reported in people with hypercholesterolemia and hypertriglyceridemia.\(^32\) People with benign pancreatic hyperenzymemia do not have pancreatic disease but have increased serum amylase, pancreatic isoamylase, and lipase activities. Obese dogs with marked postprandial hypertriglyceridemia have increased risk of increased cPLI concentrations, but not of developing clinical pancreatitis.\(^33\) Benign hyperenzymemia may occur secondary to HAC or secondary to dyslipidemia in dogs with HAC. Unfortunately, plasma cholesterol and triglyceride concentrations were not measured in this study. Although no sample had gross lipemia, hypercholesterolemia can be present in nonlipemic plasma. It remains to be determined whether a type of benign hyperenzymemia occurs in dogs and what effect it would have on these serum enzyme activities.

There were some limitations to this study. Control dogs were significantly younger than dogs with HAC. In addition, the lack of differentiation of HAC as pituitary- or adrenal-dependent complicates application of results to populations with known distributions of pituitary- and adrenal-dependent disease. Adrenal adenocarcinoma could metastasize to the pancreas or alter blood flow, affecting cPLI results. Pituitary HAC results in increased serum ACTH concentrations and possibly other hormones. The effect of such hormone increases on cPLI assay results currently is unknown.

In conclusion, dogs with HAC but without clinical pancreatitis were more likely to have abnormal SPEC concentrations and SNAP results than clinically healthy dogs with normal ACTH stimulation test results. Based on this study, abnormal cPLI results should be interpreted with caution in dogs with HAC to avoid falsely diagnosing them with concurrent pancreatitis. Additional studies are warranted to determine the pathophysiology underlying this association.

---

**Footnotes**

- SNAP cPL Test; IDEXX Laboratories, Westbrook, ME
- Cosyntropin, Amphastar, Rancho Cucamonga, CA
- Coat-A-Count, Siemens Healthcare Diagnostics, Los Angeles, CA
- MedCalc, Version 12.2.1; MedCalc Software, Mariakerke, Belgium
- SAS/STAT software, Version 9.2; SAS Institute, Cary, NC
- Steiner JM, Broussard J, Mansfield CS, et al. Serum canine pancreatic lipase immunoreactivity (cPLI) concentrations in dogs with spontaneous pancreatitis. J Vet Int Med 2001;21:274 (abstract)

**Acknowledgments**

The authors thank Ann Reed for assistance with statistical analyses and the Gastrointestinal Laboratory at Texas A&M University for performing the SPEC assays gratis.

This project was supported by a grant from the Companion Animal Fund, University of Tennessee College of Veterinary Medicine.

**Conflict of Interest Declaration**: The authors disclose no conflict of interest.

**References**

1. Feldman EC, Nelson RW. Canine hyperadrenocorticism (Cushing’s syndrome). In: Feldman E, Nelson RW, eds. Canine and Feline Endocrinology and Reproduction, 3rd ed. St. Louis, MO: Saunders; 2004:252–357.
2. Barker EN, Campbell S, Tebb AJ, et al. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005;19:810–815.
3. Hess RS, Kass PH, Shofer FS, et al. Evaluation of risk factors for fatal acute pancreatitis in dogs. J Am Vet Med Assoc 1999;214:46–51.
4. Trivedi S, Marks SL, Kass JA, et al. Sensitivity and specificity of canine pancreas-specific lipase (cPL) and other markers for pancreatitis in 70 dogs with and without histopathologic evidence of pancreatitis. J Vet Intern Med 2011;25:1241–1247.
5. Neilson-Carley SC, Robertson JE, Newman SJ, et al. Specificity of a canine pancreas-specific lipase assay for diagnosing pancreatitis in dogs without clinical or histologic evidence of the disease. Am J Vet Res 2011;72:302–307.
6. McCord K, Morley PS, Armstrong J, et al. A multi-institutional study evaluating the diagnostic utility of the Spec cPL and SNAP cPL in clinical acute pancreatitis in 84 dogs. J Vet Intern Med 2012;26:888–896.
7. Mansfield CS, Anderson GA, O’Hara AJ. Association between canine pancreatic-specific lipase and histologic exocrine pancreatic inflammation in dogs: Assessing specificity. J Vet Diagn Invest 2012;24:312–318.
8. Behrend EN, Koosistra HS, Nelson R, et al. Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM Consensus Statement (Small Animal). J Vet Intern Med 2013;27:1292–1304.
9. Steiner JM, Teague SR, Lees GE, et al. Stability of canine pancreatic lipase immunoreactivity concentration in serum
samples and effects of long-term administration of prednisone to dogs on serum canine pancreatic lipase immunoreactivity concentrations. Am J Vet Res 2009;70:1001–1005.

10. Steiner JM, Finco DR, Williams DA. Serum lipase activity and canine pancreatic lipase immunoreactivity (cPLI) concentration in dogs with experimentally induced renal failure. Vet Res 2010;3:58–63.

11. Steiner JM, Teague SR, Williams DA. Development and analytical validation of an enzyme-linked immunosorbent assay for the measurement of canine pancreatic lipase immunoreactivity in serum. Can J Vet Res 2003;67:175–182.

12. Steiner JM, Newman SJ, Xenoulis PG, et al. Sensitivity of serum markers for pancreatitis in dogs with macroscopic evidence of pancreatitis. Vet Ther 2008;9:263–273.

13. Beall MJ, Cahill R, Pigeon K, et al. Performance validation and method comparison of an in-clinic enzyme-linked immunosorbent assay for the detection of canine pancreatic lipase. J Vet Diagn Invest 2011;23:115–119.

14. Steiner JM, Xenoulis PG, Anderson JA, et al. Serum pancreatic lipase immunoreactivity concentrations in dogs treated with potassium bromide and/or phenobarbital. Vet Ther 2008;9:37–44.

15. Gaskell CL, Cribb AE. Pancreatitis associated with potassium bromide/phenobarbital combination therapy in epileptic dogs. Can Vet J 2000;41:555–558.

16. Baird-Heinz HF, Van Schoick AL, Pelsor FR, et al. A systematic review of the safety of potassium bromide in dogs. J Am Vet Med Assoc 2012;240:705–715.

17. Center SA, ManWarren T, Slater MR, Wilentz E. Evaluation of twelve-hour preprandial and two-hour postprandial serum bile acids concentrations for diagnosis of hepatobiary disease in dogs. J Am Vet Med Assoc 1991;199:217–226.

18. Smets PMY, Lefebvre HP, Meij BP, et al. Long-term follow-up of renal function in dogs after treatment for ACTH-dependent hyperadrenocorticism. J Vet Intern Med 2012;26:565–573.

19. Alenza DP, Arenas C, Lopez ML, Melian C. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism. J Am Anim Hosp Assoc 2008;42:288–278.

20. Helm JR, McLaughlan G, Boden LA, et al. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane. J Vet Intern Med 2011;25:251–260.

21. Dunn KJ, Hertridge ME, Dunn JK. Use of ACTH stimulation tests to monitor the treatment of canine hyperadrenocorticism. Vet Rec 1995;137:161–165.

22. Kintzer PP, Peterson ME. Mitotane (o, p-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 1991;5:182–190.

23. Nelp WB, Banwell JD, Hendrix TR. Pancreatic function and the viscosity of pancreatic juice before and during cortisone administration. Bull Johns Hopkins Hosp 1961;109:292–301.

24. Tiscornia OM, Hanks J, Janowitz HD, Dreiling DA. The adrenal cortex and external pancreatic secretion in the dog. J Mt Sinai Hosp N Y 1965;32:551–561.

25. Sircus W. The effect of corticotrophin and corticosteroids on the external secretion of the pancreas in dogs. Gut 1961;2:338–345.

26. Kimura T, Zuidema GD, Carmeron JL. Steroid administration and acute pancreatitis: Studies with an isolated, perfused canine pancreas. Surgery 1979;85:520–524.

27. Barzilai A, Medina A, Toth LS, Dreiling DA. The effect of steroid administration on pancreatic secretion during and after hypovolemic shock. Int J Pancreatol 1986;1:381–388.

28. Fittschen C, Bellamy JE. Prednisone treatment alters the serum amylase and lipase activities in normal dogs without causing pancreatitis. Can J Comp Med 1984;48:136–140.

29. Parent J. Effects of dexamethasone on pancreatic tissue and on serum amylase and lipase activities in dogs. J Am Vet Med Assoc 1982;180:743–746.

30. Newman S, Steiner J, Woosley K, et al. Localization of pancreatic inflammation and necrosis in dogs. J Vet Intern Med 2004;18:488–493.

31. Newman SJ, Steiner JM, Woosley K, et al. Histologic assessment and grading of the exocrine pancreas in the dog. J Vet Diagn Invest 2006;18:115–118.

32. Cavalini G, Frulloni L, Vaona B, et al. Is hyperamylasemia related to dyslipidemia? [letter to the editor]. Gastroenterology 1997;112:1058.

33. Verkest KR, Fleeman LM, Morton JM, et al. Association of postprandial serum triglyceride concentration and serum canine pancreatic lipase immunoreactivity in overweight and obese dogs. J Vet Intern Med 2012;26:46–53.
Dear Dr. ___________________________:

We are currently performing a study utilizing leftover sera from dogs that received ACTH stimulation testing. Your clinic recently submitted an ACTH stimulation test to the UT Endocrinology Laboratory. We would greatly appreciate it if you would confirm the patient’s signalment and answer a few brief questions. Provision of this information is anticipated to take no longer than 5 minutes.

Name: ____________________________ Breed: ______________________________
Gender: M / F (circle one) Neutered?: Y / N (circle one)
Year of birth: ___________________

Please check (√) the box next to the disease you were evaluating with ACTH stimulation testing:
- Hyperadrenocorticism (Cushings)
- Hypoadrenocorticism (Addisons)
- Hyperadrenocorticism (Treatment evaluation, i.e. Currently receiving Mitotane or trilostane)

Please check (√) the boxes next to all clinical signs present at time of ACTH stimulation test:
- Anorexia or hyporexia
- Polyphagia
- Vomiting
- Polyuria/polydipsia
- Diarrhea
- Panting
- Abdominal pain
- Other:__________________________

Please list any laboratory abnormalities present at time of ACTH stimulation test or send a copy of your blood work:
________________________________________________________________________
________________________________________________________________________

Please list any medications the patient was receiving at the time of ACTH stimulation test:
________________________________________________________________________
________________________________________________________________________

Additional comments?
________________________________________________________________________
________________________________________________________________________

Thank you so much for your time and effort to make this project possible. You may receive a follow up phone call regarding this study in the next couple of days.

Appendix : Questionnaire for enrollment of dogs with HAC

Dear Dr. ___________________________:

We are currently performing a study utilizing leftover sera from dogs that received ACTH stimulation testing. Your clinic recently submitted an ACTH stimulation test to the UT Endocrinology Laboratory. We would greatly appreciate it if you would confirm the patient’s signalment and answer a few brief questions. Provision of this information is anticipated to take no longer than 5 minutes.

Name: ____________________________ Breed: ______________________________
Gender: M / F (circle one) Neutered?: Y / N (circle one)
Year of birth: ___________________

Please check (√) the box next to the disease you were evaluating with ACTH stimulation testing:
- Hyperadrenocorticism (Cushings)
- Hypoadrenocorticism (Addisons)
- Hyperadrenocorticism (Treatment evaluation, i.e. Currently receiving Mitotane or trilostane)

Please check (√) the boxes next to all clinical signs present at time of ACTH stimulation test:
- Anorexia or hyporexia
- Polyphagia
- Vomiting
- Polyuria/polydipsia
- Diarrhea
- Panting
- Abdominal pain
- Other:__________________________

Please list any laboratory abnormalities present at time of ACTH stimulation test or send a copy of your blood work:
________________________________________________________________________
________________________________________________________________________

Please list any medications the patient was receiving at the time of ACTH stimulation test:
________________________________________________________________________
________________________________________________________________________

Additional comments?
________________________________________________________________________
________________________________________________________________________

Thank you so much for your time and effort to make this project possible. You may receive a follow up phone call regarding this study in the next couple of days.